Rildo: Real-World Multicenter Study on the Effectiveness and Safety of Single-Tablet Regimen of Dolutegravir plus Rilpivirine in Treatment-Experienced People Living with HIV

Two-drug regimens (2DRs) are emerging in clinical practice guidelines as treatment option for both naive and treatment-experienced people living with HIV (PLHIV). <b>Objectives:</b> To determine the real-life effectiveness of 2DR with 25 mg RPV plus 50 mg DTG in a single-tablet regimen (RPV/DTG<sub>...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Carmen Hidalgo-Tenorio, David Vinuesa, Coral García-Vallecillos, Leopoldo Muñoz-Medina, Sergio Sequera, Rosario Javier, Miguel Ángel López-Ruz, Svetlana Sadyrbaeva-Dolgova, Juan Pasquau
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2022-11-01
Edice:	Viruses
Témata:	2DR dolutegravir rilpivirine treatment-experienced PLHIV
On-line přístup:	https://www.mdpi.com/1999-4915/14/12/2626
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!